Thrombolysis in ischemic stroke: Focus on new treatment strategies

Research output: Contribution to journalArticlepeer-review


Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.

Original languageEnglish
Pages (from-to)42-52
Number of pages11
JournalRecent Patents on Cardiovascular Drug Discovery
Issue number1
Publication statusPublished - Apr 2012


  • Bridging
  • Intra-arterial thrombolysis
  • Intravenous thrombolysis
  • Mechanical clot retrieval
  • Patents thrombolytic agents
  • Rtpa
  • Sonothrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery


Dive into the research topics of 'Thrombolysis in ischemic stroke: Focus on new treatment strategies'. Together they form a unique fingerprint.

Cite this